PDCD1 and ovarian carcinoma: In summary, PD-1/LAG-3 blockade with tebotelimab enhances immune responses above those achieved by PD-1 inhibition alone, as demonstrated in various preclinical settings, and confers clinical responses in patients typically unresponsive to PD-1 inhibition, such as those with ovarian cancer and DLBCL.